KALA BIO, Inc. (KALA) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Today's conference is scheduled to begin shortly. Please continue to stand by. Thank you. Thank you. Good morning and welcome to College Pharmaceutical's second quarter 2021 financial results conference call. At this time, our participants are in a listen-only mode. Following management's prepared remarks, a Q&A session will be held. As a reminder, this call is being recorded. I would like to turn the conference over to Naranjan Kimiswaran, Senior Vice President of Strategy of College Pharmaceutical. Please proceed. Thank you, Operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwiki, Chairman, President, and Chief Executive Officer, Todd Baysmore, Chief Operating Officer, Mary Remoth, Chief Financial Officer, and Kim Brazel, our Chief Medical Officer, will also be joining us for the Q&A portion of today's call. Today's call is being webcast live. The webcast link can be found in the Investors and Media section of our website at www.kalaRx.com. During this call, we will be referring to non-GAAP financial measures which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today, which can also be found on our website. On this call, we will make certain comments about CALA's future expectations, plans, and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include statements regarding the potential market and commercial launch plans for ISUVIS, observations associated with our commercialization of ISUVIS and INBELTIS, and the sufficiency of our cash resources. These and...